Scarica l'app Stockscreener
29.69
2.34%
0.68
Dopo l'orario di chiusura:
29.72
0.03
+0.10%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RARE Giù?
Forum
Previsione
Frazionamento azionario
Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie
What are analysts’ price targets for Ultragenyx Pharmaceutical Inc.July 2025 Action & Verified Chart Pattern Trade Signals - sundaytimes.kr
Ultragenyx Investors Investigated for Securities Fraud and Unlawful Practices. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2025 Earnings Call Transcript - MSN
Ultragenyx Says CRL Discussions ‘Productive’ Despite US FDA Leadership Upheaval - insights.citeline.com
Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143 - Insider Monkey
Sarepta’s Woes Put the Stalwart AAV Under a Harsh Light - BioSpace
Cantor Fitzgerald Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $105.00 - MarketBeat
Reversal indicators forming on Ultragenyx Pharmaceutical Inc. stockWeekly Growth Portfolio Performance Summary - Newser
Technical Charts Suggest Momentum Shift in Ultragenyx Pharmaceutical Inc.Potential Breakout Stock List Published This Week - beatles.ru
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
How Ultragenyx Pharmaceutical Inc. stock performs during market volatilityFree Triple Digit Return Stock Predictions - Newser
Signal strength of Ultragenyx Pharmaceutical Inc. stock in tech scannersHigh Conviction Stock Long-Term Summary - Newser
Why Ultragenyx Pharmaceutical Inc. stock attracts strong analyst attentionFree Weekly Setup With 3x Return Potential - Newser
Ultragenyx's Q2 earnings exceed expectations, price target lowered to $128 by Canaccord. - AInvest
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
Ultragenyx Pharmaceutical Analyst Ratings: Recent Assessments and Insights - AInvest
What makes Ultragenyx Pharmaceutical Inc. stock price move sharplyEquity Portfolio Outlook and Performance Summary - Newser
RBC Capital Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
FDA requests manufacturing changes for UX111 gene therapy - Sanfilippo Syndrome News
Ultragenyx Bets On Growth With Bullish Analyst Backing - Finimize
Ultragenyx Pharmaceutical Q2 2025 Earnings: Revenue Beats Expectations, Loss Narrows - AInvest
Ultragenyx Pharmaceutical Second Quarter 2025 Earnings: Beats Expectations - ca.finance.yahoo.com
‘Urgent need’ for treatment drives GTX-102 study enrollment - Angelman Syndrome News
Ultragenyx Pharmaceutical Inc. stock momentum explainedFree Proven Entry Plan With Low Risk Trade - Newser
Ultragenyx Earnings Call: Clinical Wins Amid Financial Challenges - TipRanks
‘On track to become profitable’: Marin County rare disorder drug maker narrows loss in Q2 - The North Bay Business Journal
Aspire Biopharma Holdings, Inc. shares rise 4.06% after-hours following Ultragenyx Pharmaceutical Inc. Q2 2025 earnings call. - AInvest
S&E In Brief: Launch Trends And Regulatory Updates Among SMID Biopharmas - insights.citeline.com
Ultragenyx Pharmaceutical: Strong Q2 Results and Promising Future Justify Buy Rating - TipRanks
Ultragenyx (RARE) Q2 Revenue Up 13% - Nasdaq
Ultragenyx Pharmaceutical Inc. SEC 10-Q Report - TradingView
Ultragenyx Pharmaceutical Q2 2025 Earnings Call Transcript - MarketBeat
Ultragenyx outlines $640M–$670M 2025 revenue target as clinical milestones advance - MSN
Ultragenyx: Q2 Earnings Snapshot - New Haven Register
Price action breakdown for Ultragenyx Pharmaceutical Inc.Long Term Equity Screener with Safety Metrics - Newser
Ultragenyx Pharmaceutical Inc (RARE) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Ultragenyx Pharmaceutical Inc (RARE) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Ultragenyx Pharmaceuticals: A High-Stakes Play in Rare Disease Gene Therapy - AInvest
Ultragenyx's Q2 2025 Earnings Call: Dissecting Contradictions on Setrusumab Efficacy, FDA Interactions, and Resubmission Strategy - AInvest
Ultragenyx Pharmaceutical Q2 2025 Earnings Call Transcript: Financial Results and Business Update - AInvest
Ultragenyx Sets 2025 Revenue Target at $640M-$670M Amid Clinical Advancements - AInvest
Ultragenyx Reports Growth Amidst Strategic Advancements - TipRanks
Earnings call transcript: Ultragenyx Q2 2025 beats EPS forecast, stock rises - Investing.com
Transcript : Ultragenyx Pharmaceutical Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Ultragenyx Reports Better-Than-Expected Q2 Loss and RevenueNews and Statistics - IndexBox
Ultragenyx Pharmaceutical Inc reports results for the quarter ended June 30Earnings Summary - TradingView
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):